. 2014 Jun 16;9:629–645. doi: 10.2147/COPD.S61717

Table 2.

Adjusted mean FEV₁ responses (difference from placebo) at key time points

Mean (SE) difference AUC_0–3 from placebo, L Week	Study 1222.11		Study 1222.12
Mean (SE) difference AUC_0–3 from placebo, L Week	Olodaterol 5 μg (n=206)	Olodaterol 10 μg (n=206)	Olodaterol 5 μg (n=207)	Olodaterol 10 μg (n=215)
12 (coprimary end point)	0.172 (0.019)^****	0.176 (0.019)^****	0.151 (0.017)^****	0.143 (0.017)^****
24	0.174 (0.019)^****	0.161 (0.019)^****	0.165 (0.018)^****	0.136 (0.018)^****
48	0.173 (0.019)^****	0.169 (0.020)^****	0.161 (0.018)^****	0.158 (0.018)^****
Mean (SE) trough difference from placebo, L Week	Study 1222.11		Study 1222.12
Mean (SE) trough difference from placebo, L Week	Olodaterol 5 μg (n=199)	Olodaterol 10 μg (n=202)	Olodaterol 5 μg (n=205)	Olodaterol 10 μg (n=207)

12 (coprimary end point)	0.091 (0.019)^****	0.101 (0.019)^****	0.047 (0.019)^*	0.048 (0.019)^**
24	0.086 (0.019)^****	0.089 (0.019)^****	0.069 (0.019)^***	0.058 (0.019)^**
48	0.092 (0.019)^****	0.091 (0.019)^****	0.068 (0.019)^***	0.071 (0.019)^***

Notes:

P<0.05;

^**

P<0.01;

^***

P<0.001;

^****

P<0.0001. Number of patients in the placebo arm of the AUC_0–3 analysis was 208 for 1222.11 and 215 for 1222.12. Number of patients in the placebo arm of the trough difference analysis was 200 for 1222.11 and 205 for 1222.12.

Abbreviations: FEV₁, forced expiratory volume in 1 second; SE, standard error; AUC_0–3, area under the curve from 0–3 hours.